Sugi Predict

Sugi Predict / Compounds / SCHEMBL3700526

SCHEMBL3700526

SCHEMBL3700526

COC(=O)C1(CC(=O)OC(C)(C)C)Cc2ccccc2C1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 1/20 0.37
▸ GHSR Q92847 1/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ MMP1 P03956 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ PTPRC P08575 2/20 0.34
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30267728 1.00 MME (0.37) MMEGHSREPHX2NAMPTMMP1
SCHEMBL29193914 0.91 POLB (0.36) MMEGHSREPHX2NAMPTPOLB
SCHEMBL260291 0.86 BRD4 (0.43) GHSRPOLBL3MBTL1MEN1NPC1
SCHEMBL260410 0.85 MME (0.38) MMEGHSREPHX2NAMPTPOLB
SCHEMBL29456934 0.85 MME (0.38) MMEGHSREPHX2NAMPTPOLB
SCHEMBL8902403 0.84 LMNA (0.34) —
SCHEMBL8903076 0.84 PKM (0.32) MAPT
SCHEMBL30492980 0.84 GHSR (0.35) MMEGHSREPHX2NAMPTPTPRC
SCHEMBL20511925 0.83 MTNR1A (0.38) POLBMAPT
SCHEMBL30492987 0.83 MTNR1A (0.38) POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12286411-B2 Indane derivatives for use in the treatment of bacterial infection ANTABIO SAS (FR) 2025-04-29 — — US disclosed
US-12247013-B2 Indane derivatives for use in the treatment of bacterial infection ANTABIO SAS (FR) 2025-03-11 — — US disclosed
CN-113166084-B Indane derivatives for the treatment of bacterial infections 安塔比奥公司 2024-06-04 — — CN disclosed
US-20240016941-A1 COMBINATION THERAPY ANTABIO SAS (FR) 2024-01-18 — — US disclosed
US-20240016941-A1 COMBINATION THERAPY ANTABIO SAS (FR) 2024-01-18 — — US disclosed
US-20240016941-A1 COMBINATION THERAPY ANTABIO SAS (FR) 2024-01-18 — — US disclosed
EP-3601224-B1 CHEMICAL COMPOUNDS AS ANTIBIOTICS ANTABIO SAS (FR) 2023-07-05 — — EP disclosed
EP-4125883-A1 COMBINATION THERAPY Antabio SAS (FR) 2023-02-08 — — EP disclosed
US-20220112169-A1 INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION ANTABIO SAS (FR) 2022-04-14 — — US disclosed
US-20210347748-A1 INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION ANTABIO SAS (FR) 2021-11-11 — — US disclosed
US-8877815-B2 Substituted carbamoylcycloalkyl acetic acid derivatives as NEP NOVARTIS AG (CH) 2014-11-04 — — US disclosed
EP-2640689-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS Novartis AG (CH) 2013-09-25 — — EP disclosed
WO-2012065953-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS NOVARTIS AG (CH) 2012-05-24 — — WO disclosed
US-20120122764-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP NOVARTIS AG (CH) 2012-05-17 — — US disclosed
US-20120122764-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP NOVARTIS AG (CH) 2012-05-17 — — US disclosed
US-20120122764-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP NOVARTIS AG (CH) 2012-05-17 — — US disclosed
US-5591739-A 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE MERRELL PHARMACEUTICALS INC. (US) 1997-01-07 — — US disclosed
EP-0534396-B1 2-Substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace MERRELL PHARMA INC (US) 1996-10-09 — — EP disclosed
US-5457196-A Analgesics, hypotensive agents MERRELL DOW PHARMACEUTICALS INC. (US) 1995-10-10 — — US disclosed
EP-0534396-A2 2-Substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace MERRELL PHARMACEUTICALS INC. (US) 1993-03-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112169-A1 INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION ARG1, ELANE, INSR MME 477/4885GHSR 1105/4885EPHX2 4328/4885
US-12286411-B2 Indane derivatives for use in the treatment of bacterial infection ELANE, ARG1, INSRR MME 436/4885GHSR 1022/4885EPHX2 4513/4885
US-20240016941-A1 COMBINATION THERAPY CFTR, ABCB11, SLC26A4 MME 1857/4885GHSR 337/4885EPHX2 3077/4885
US-20120122764-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP MME, REN, ECE1 MME 1/4885GHSR 1833/4885EPHX2 333/4885
US-12247013-B2 Indane derivatives for use in the treatment of bacterial infection ELANE, ARG1, INSRR MME 436/4885GHSR 1022/4885EPHX2 4513/4885
US-20210347748-A1 INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION INSR, INSRR, ARG1 MME 631/4885GHSR 1024/4885EPHX2 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.